• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Mirna Therapeutics

edit

Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Milestones

edit

• 
  Mirna Therapeutics added Paul Lammers as President & CEO.
  Posted 12/17/09 at 6:31am
• 
  Mirna Therapeutics added Matt Winkler as Chairman.
  Posted 12/17/09 at 6:31am
• 
  Mirna Therapeutics received $34.5M in Series C funding. (10/24/12)
  Posted 10/25/12 at 5:21am via finsmes.com
• 
  Mirna Therapeutics received $1.5M in Venture Round funding. (8/23/11)
  Posted 8/23/11 at 5:56pm via finsmes.com
• 
  Mirna Therapeutics received $5M in Grant funding. (12/16/09)
  Posted 12/17/09 at 6:31am via dowjones.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/17/09

Sources

1. Mirna Therapeutics Taps Texas For $5M, Bulks Up Board (fis.dowjones.com) [edit]
2. Mirna Therapeutics Closes $1.5M Equity Financing Round (finsmes.com) [edit]
3. Mirna Therapeutics Completes $34.5M Series C Financing (finsmes.com) [edit]